Inveready leads €5m investment in biotech startup Oxolife

State-backed Center for Industrial Technological Development (CDTI) also took part in the round, alongside BStartup, HighStick and other private investors.

Inveready deployed capital through its €30m fund Inveready Biotech III. 

With this investment, Oxolife intends to expand the phase-I study of its Oxo-001 molecule and conduct a phase-II clinical trial across Spain and the rest of Europe. Subsequently, the company plans to reach an agreement with a pharmaceutical company to complete the clinical development and market its drug by 2023.

Previous funding
The company raised €1.2m from various private investors through the Capital Cell platform in early 2020.

Company
Founded in 2013 and based in Barcelona, Oxolife develops a molecule, Oxo-001, that acts on embryo implantation to increase the pregnancy success rate.

The company completed a first phase-I study for Oxo-001 and is currently advancing the phase-II clinical trial to demonstrate the new treatment's effectiveness.

People
Inveready – Roger Piqué (general partner); Sara Secall (life science operating partner).
Oxolife – Agnès Arbat (CEO, co-founder); Ignasi Canals (co-founder).

Advisers
Equity – DWF-RCD (legal); Lexcrea (legal).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Southern Europe
• Healthcare
• Venture
• Inveready First Capital
• Spain